CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today four presentations from scientific collaborators at the upcoming American Society for Clinical Oncology (ASCO) Annual Meeting, taking place June 2 – 6, 2023, in Chicago, Illinois.

The abstracts are currently available on the ASCO meeting website. The posters will be available online at following the presentations.

Poster Presentation Details:

In silico approaches to patient selection: Credentialing elraglusib as a novel treatment in metastatic melanoma resistant to checkpoint inhibitors.
Presentation Type: Poster Presentation
Date/Time: Saturday, June 3, 2023, 8:00 AM – 11:00 AM
Presenter: Joseph McDermott, Lantern Pharma Inc., Dallas TX
Abstract Number: 3079

Phase 2 study of elraglusib (9-ING-41), a glycogen synthase kinase-3b inhibitor, in combination with gemcitabine plus nab-paclitaxel (GnP) in patients with previously untreated advanced pancreatic ductal adenocarcinoma (PDAC).
Presentation Type: Online Publication
Presenter: Dr. Devalingam Mahalingam, Northwestern University, Chicago, IL
Abstract Number: e16289

Plasma cytokine profiles and survival outcomes in the 1801 phase 1/2 clinical trial of 9-ING-41 (elraglusib) in patients with advanced cancer.
Presentation Type: Online Publication
Presenter: Taylor Weiskittel, Mayo Clinic, Rochester, MN
Abstract Number: e14555

GSK-3 inhibitor elraglusib (9-ING-41) to enhance tumor-infiltrating immune cell activation in tumor biopsies and synergize with anti-PD-L1 in a murine model of colorectal cancer.
Presentation Type: Online Publication
Presenter: Dr. Wafik S. El-Deiry, Brown University, Providence, RI
Abstract Number: e15138

About Actuate Therapeutics, Inc.
Actuate is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for high impact cancers and inflammatory diseases. Actuate’s lead drug, elraglusib (a novel GSK-3 inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy. Elraglusib is also emerging as a mediator of anti-tumor immunity through the inhibition of multiple immune checkpoints and the regulation of immune cell function. For additional information, please visit the Company’s website at

Public Relations Dept.,
Actuate Therapeutics, Inc.
+1 (847) 986-4190